Sign In
Get Clay Free →

Suggestions

    Eric Schadt

    Professor, Icahn School of Medicine at Mount Sinai

    Professional Background

    Eric Schadt is a preeminent figure in the fields of precision medicine and genomics, boasting a career that spans over two decades in academic and corporate leadership roles. After an illustrious tenure at Sema4, where he catalyzed significant growth including the company's public listing and a successful merger with GeneDx, Eric opted to return to his scientific roots. In August 2022, he took on the role of Dean for Precision Medicine and Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai.

    In his current position, Eric continues to forge new paths in precision medicine, leveraging extensive genomic data, clinical information, and digital health resources to redefine the standards of patient care. His mission is to empower patients in collaboration with their healthcare providers, utilizing predictive models to understand disease mechanisms and inform clinical decision-making.

    Prior to his impactful work with Sema4, Eric was the Founding Director of the Icahn Institute for Genomics and Multiscale Biology, as well as Chair of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine. He has played pivotal roles in establishing innovative research organizations and companies designed to advance the understanding of human diseases and improve therapeutic outcomes.

    Education and Achievements

    Eric Schadt's academic journey is as impressive as his professional achievements. He earned his Bachelor of Science degree in Applied Mathematics and Computer Science from California Polytechnic State University-San Luis Obispo. Following that, he obtained a Master of Arts in Pure Mathematics from the University of California, Davis, and culminated his educational pursuits with a Ph.D. in Biomathematics from the University of California, Los Angeles (UCLA). His education provided a solid foundation in various disciplines, fostering an exceptional aptitude for integrating mathematics and biology.

    Eric's commitment to advancing genomics and precision medicine has resulted in over 500 peer-reviewed publications in esteemed scientific journals. He has significantly contributed to the understanding of various diseases, including diabetes, obesity, and Alzheimer's disease, establishing himself as a thought leader in the field. His work not only reflects a deep understanding of the molecular underpinnings of diseases but also emphasizes the importance of applying these insights to groundbreaking clinical applications.

    Specializations

    Eric's expansive expertise encompasses a multitude of specialties essential for driving innovation and research within life sciences. These include mathematics, statistics, computing, and their applications within biology and genomics. He is adept in systems genetics and systems biology, utilizing high-performance computing techniques to tackle complex, large-scale scientific research challenges. Furthermore, his leadership abilities shine through in his capacity to build and guide high-performing research teams, consistently addressing pressing problems in biomedical sciences.

    Eric has also demonstrated proficiency in drug discovery and development, contributing to the advancement of pharmacogenetics and pharmacogenomics, which explore the impact of genetics on drug response. His involvement in clinical trials further underscores his dedication to translating scientific discoveries into actionable healthcare advancements.

    Key Career Milestones

    Throughout his remarkable career, Eric has held pivotal roles, including being a Chief Scientist at Rosetta Inpharmatics, an Executive Director at Merck, and the Chief Scientific Officer at Pacific Biosciences. His contributions have been instrumental in shaping the strategic direction of these organizations and fostering a culture of innovation and discovery.

    At Sema4, where he served as the Founder, President, and Chief R&D Officer, Eric's vision was crucial in guiding the company's journey from its inception to being a publicly traded entity. The successful merger with GeneDx exemplifies his strategic foresight and dedication to expanding the potential of precision medicine in clinical practice.

    As a former Board Member and Co-Founder of Sage Bionetworks, Eric has been integral to the advancement of open science principles. His ethical approach to data sharing and collaborative research has positioned him as a champion for transparency and inclusivity in scientific endeavor.

    Looking Ahead

    Eric Schadt remains dedicated to carving out new dimensions in the realm of genomic research and personalized healthcare. By continuing to utilize and expand his extensive experience, he aims to bridge the gap between molecular biology and clinical practice, making personalized treatment accessible and effective for all patients. His leadership at the Icahn School of Medicine at Mount Sinai is a testament to his commitment to enhancing healthcare through groundbreaking scientific research and innovation.

    Eric's multifaceted expertise positions him at the forefront of genetic and biomedical research, where he actively participates in shaping the future landscape of healthcare. His continued focus on utilizing next-generation sequencing (NGS) and multiomic data sets reflects a forward-thinking approach that is pivotal for the evolution of precision medicine and patient care.

    Related Questions

    What motivated Eric Schadt to shift back to a science-focused role at the Icahn School of Medicine after his success at Sema4?
    How does Eric Schadt plan to leverage existing genomic data at the Icahn School of Medicine to enhance patient outcomes?
    What are some of the key collaborative projects Eric Schadt is involved with in his role as Dean for Precision Medicine?
    How has Eric Schadt's educational background in mathematics and computer science informed his approach to genomics and precision medicine?
    What advancements in precision medicine does Eric Schadt envision in the next five to ten years, based on his current research initiatives?
    Eric Schadt
    Add to my network

    Location

    New York, New York, United States